Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $71.67 in the prior trading day, BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $72.7, up 1.44%. In other words, the price has increased by $1.44 from its previous closing price. On the day, 1.61 million shares were traded. BBIO stock price reached its highest trading level at $73.0599 during the session, while it also had its lowest trading level at $70.35.
Ratios:
Our goal is to gain a better understanding of BBIO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 3.88.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $66.
On July 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $70.Jefferies initiated its Buy rating on July 14, 2025, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 08 ’25 when Apuli Maricel sold 2,000 shares for $74.26 per share. The transaction valued at 148,520 led to the insider holds 130,297 shares of the business.
Kumar Neil sold 40,000 shares of BBIO for $2,975,913 on Dec 04 ’25. The Chief Executive Officer now owns 775,686 shares after completing the transaction at $74.40 per share. On Dec 05 ’25, another insider, Kumar Neil, who serves as the Chief Executive Officer of the company, sold 40,000 shares for $73.31 each. As a result, the insider received 2,932,563 and left with 755,686 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 14009930752 and an Enterprise Value of 15234066432. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.60. Its current Enterprise Value per Revenue stands at 43.061 whereas that against EBITDA is -26.582.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.18, which has changed by 1.5901699 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $75.10, while it has fallen to a 52-week low of $25.34. The 50-Day Moving Average of the stock is 15.62%, while the 200-Day Moving Average is calculated to be 55.78%.
Shares Statistics:
The stock has traded on average 2.30M shares per day over the past 3-months and 1743340 shares per day over the last 10 days, according to various share statistics. A total of 192.63M shares are outstanding, with a floating share count of 164.53M. Insiders hold about 14.62% of the company’s shares, while institutions hold 87.80% stake in the company. Shares short for BBIO as of 1764288000 were 19381854 with a Short Ratio of 8.43, compared to 1761868800 on 19566757. Therefore, it implies a Short% of Shares Outstanding of 19381854 and a Short% of Float of 16.790001.
Earnings Estimates
The performance of BridgeBio Pharma Inc (BBIO) in the stock market is under the watchful eye of 3.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.58 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$2.77 and -$3.59 for the fiscal current year, implying an average EPS of -$3.19. EPS for the following year is -$1.77, with 3.0 analysts recommending between -$1.6 and -$1.94.
Revenue Estimates
17 analysts predict $148.15M in revenue for. The current quarter. It ranges from a high estimate of $217.49M to a low estimate of $125.96M. As of. The current estimate, BridgeBio Pharma Inc’s year-ago sales were $5.88MFor the next quarter, 17 analysts are estimating revenue of $169.69M. There is a high estimate of $205.1M for the next quarter, whereas the lowest estimate is $141.8M.
A total of 18 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $565.39M, while the lowest revenue estimate was $456.4M, resulting in an average revenue estimate of $494.85M. In the same quarter a year ago, actual revenue was $221.9MBased on 16 analysts’ estimates, the company’s revenue will be $888.89M in the next fiscal year. The high estimate is $1.24B and the low estimate is $723.7M.
